Cerus Corporation (NASDAQ:CERS) Closed Higher Than Its 50 Day Average


The stock last traded at $2.94 which is just a bit higher than $2.80, the 50 day moving average and barely above the 200 day moving average of $2.80. The 50 day moving average was up $0.14 and the 200 day average went up by +4.84%. Trading volume for Cerus Corporation was 589K by the end of trading on Tuesday. Shares saw a steep decrease in trading volume of 76.24% under the normal average daily volume.

Investors are a little more bullish on Cerus Corporation of late if you pay attention to the decrease in short interest. The firm experienced a fall in short interest of -19.78% as of September 29, 2017 from the last reporting period. Short interest decreased 2,094,873 over that timeframe. With short interest at 8,496,127 and short average daily volume at 644,856, days to cover is 13.0 and the percentage of shorted shares is 0.08% as of September 29.

The following firms have recently changed their position in CERS. As of the end of the quarter Bronfman E.l. Rothschild, L.p. had bought a total of 12,500 shares growing its stake by 166.7%. The value of the investment in Cerus Corporation went from $33,000 to $50,000 increasing 51.5% since the last quarter. As of quarter end Ubs Group Ag had acquired 51,057 shares growing its holdings by 1,211.9%. The value of the investment in CERS increased from $19,000 to $139,000 a change of $120,000 for the reporting period.

As of the end of the quarter Baird Financial Group, Inc. had disposed of 92,610 shares trimming its position 47.5%. The value of the total investment in Cerus Corporation decreased from $868,000 to $257,000 a change of 70.4% quarter to quarter. As of quarter end Berson & Corrado Investment Advisors, LLC had acquired 40,475 shares growing its holdings by 124.7%. The value of the investment in (CERS) increased from $81,000 to $199,000 increasing 145.7% quarter over quarter.

In the last earnings report the EPS was $-0.61 and is expected to be $-0.64 for the current year with 109,137,000 shares currently outstanding. Next quarter’s EPS is estimated at $-0.16 with next year’s EPS anticipated to be $-0.48.

Cerus Corporation, launched on July 31, 1996, is a biomedical products company. The Company is involved in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Business’s INTERCEPT Blood System is based on its technology for controlling biological replication and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Business’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Business’s INTERCEPT Blood System is for use with three blood components: plasma, platelets, and red blood cells..